Nav: Home

Drug that keeps surface receptors on cancer cells makes them more visible to immune cells

March 05, 2020

A drug that is already clinically available for the treatment of nausea and psychosis, called prochlorperazine (PCZ), inhibits the internalization of receptors on the surface of tumor cells, thereby increasing the ability of anticancer antibodies to bind to the receptors and mount more effective immune responses. PCZ enhanced the ability of anticancer antibodies to reduce tumor growth in mice, by temporarily increasing the clustering of a receptor targeted by anticancer antibodies on the surface of tumor cells. Temporary treatment of cancer patients with PCZ similarly resulted in receptor clustering on tumor cells inside of patients. The work appears March 5 in the journal Cell.

"This represents a potentially disruptive change in clinical approaches to improve therapeutic targeting as the opportunity of temporarily moving drug targets within patient tumor cells becomes possible," says senior author Fiona Simpson, a cancer researcher at the University of Queensland.

In addition to treating nausea and psychosis, PCZ is currently used in laboratory studies as an inhibitor of endocytosis, a process by which substances are brought into the cell. The temporary inhibition of endocytosis via molecules such as PCZ has been proposed for numerous clinical applications, including control of viral infection, epilepsy, and chronic kidney disease.

To help move this approach closer to clinical translation, Simpson and her team recently developed an imaging method to reliably measure endocytosis in humans. When they analyzed tumor samples from patients with squamous cell carcinoma, they found that a decrease in endocytosis of a protein called epidermal growth factor receptor (EGFR) was associated with better clinical responses to the cancer drug cetuximab, an antibody that binds to and inhibits EGFR. "We found that if we stopped the drug targets getting inside the cells by inhibiting the uptake process, called endocytosis, we got a really big immune response against the tumors in mice," Simpson says.

"This led to the concept that temporarily halting endocytosis of receptors that are the targets of monoclonal antibody therapies may be used to improve clinical outcomes," Simpson says. Their findings suggested that endocytosis inhibition in humans, which increases the clustering of EGFR on the surface of tumor cells, thereby increasing the availability of the receptor for binding to the antibody, should lead to improved outcomes for patients treated with certain therapeutic antibodies.

Exploring this idea in the new study with a different therapeutic antibody, Simpson and her team showed that PCZ improved the immune responses of tumor cells to cetuximab. In mice with cancer, combination therapy with PCZ and cetuximab reversed resistance to cetuximab therapy and inhibited tumor growth more than either treatment alone. Similarly, combination therapy with PCZ and avelumab--an anticancer antibody that inhibits a protein called programmed death ligand 1 (PD-L1)--inhibited tumor growth in mice more than either treatment alone. "These findings highlight the crucial role of availability and persistence of the molecule targeted by the therapeutic antibody at the cell surface of tumor cells," Simpson says.

To begin to test the safety of this approach in humans, Simpson and her team carried out an open-label, uncontrolled, single-center proof-of-concept study in which a single dose of PCZ was intravenously administered to patients with squamous cell carcinoma of the head and neck. Tumor biopsies were taken before and after PCZ treatment. Analysis of results from four patients showed that PCZ increased cetuximab binding sites and the clustering of EGFR on the surface of tumor cells. "As far as we can tell, this was the first verified manipulation of endocytosis in humans," Simpson says.

Moreover, tumor cells became more homogenous with regard to the availability of cetuximab binding sites. "In our patients, we could see surface target on some tumor cells exposed and not others. After PCZ, they all had drug target on their surface, so it fixed the heterogeneity problem," Simpson says. "By overcoming the heterogeneity of drug target availability that frequently characterizes poorly responsive or resistant tumors, clinical application of PCZ may considerably improve the clinical benefit of therapeutic antibodies."

PCZ is already prescribed chronically in some people for the management of psychosis. Unfortunately, over a lifetime of PCZ use, patients may show an increased incidence of metabolic syndrome. But, in this case, the proposed use of the drug by Simpson and colleagues is shortterm, and the endocytosis inhibition is reversible, negating the side effects of chronic use. "It turns out PCZ at the high concentration we use it only stops trafficking for about four hours," Simpson says. "This is enough time to line up the immune cells when an antibody drug is used against the tumor cells," but theoretically not enough time to be really toxic. Further clinical studies are underway to fully test whether this approach can be safely used in people.

From a broader perspective, the study sets the stage for testing PCZ in clinical trials to treat epilepsy or chronic kidney disease or to improve the effectiveness of anti-HIV antibodies. According to the authors, the drug might also be used as a frontline medicine to prevent or reduce infections by highly pathogenic viruses such as dengue or Ebola.

Currently, Simpson and her collaborators are conducting a phase IB safety trial to test the combination of cetuximab and PCZ in head and neck cancer, triple-negative breast cancer and adenoid cystic carcinoma. "We need to show efficacy through trials first, but if it works, we could use it to improve therapies in lots of different cancers and also other uses," Simpson says. "We are hoping once the idea is out there, lots of clever people will run with the idea and make it work even better."
-end-
This work was supported by a University of Queensland IPRS scholarship, UQ International scholarships, a NHMRC Career Development Award, Cancer Council Queensland, the National Breast Cancer Foundation, the Queensland Head and Neck Cancer Centre, the International Rotary Club, and the Princess Alexandra Research Foundation. Further declarations of interest are listed in the paper.

Cell, Chew, De Lima, Gonzalez Cruz, Banushi, Echejoh, Hu, and Joseph et al.: "Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies" https://www.cell.com/cell/fulltext/S0092-8674(20)30163-X(20)30163-X

Cell (@CellCellPress), the flagship journal of Cell Press, is a bimonthly journal that publishes findings of unusual significance in any area of experimental biology, including but not limited to cell biology, molecular biology, neuroscience, immunology, virology and microbiology, cancer, human genetics, systems biology, signaling, and disease mechanisms and therapeutics. Visit: http://www.cell.com/cell. To receive Cell Press media alerts, contact press@cell.com.

Cell Press

Related Science Articles:

75 science societies urge the education department to base Title IX sexual harassment regulations on evidence and science
The American Educational Research Association (AERA) and the American Association for the Advancement of Science (AAAS) today led 75 scientific societies in submitting comments on the US Department of Education's proposed changes to Title IX regulations.
Science/Science Careers' survey ranks top biotech, biopharma, and pharma employers
The Science and Science Careers' 2018 annual Top Employers Survey polled employees in the biotechnology, biopharmaceutical, pharmaceutical, and related industries to determine the 20 best employers in these industries as well as their driving characteristics.
Science in the palm of your hand: How citizen science transforms passive learners
Citizen science projects can engage even children who previously were not interested in science.
Applied science may yield more translational research publications than basic science
While translational research can happen at any stage of the research process, a recent investigation of behavioral and social science research awards granted by the NIH between 2008 and 2014 revealed that applied science yielded a higher volume of translational research publications than basic science, according to a study published May 9, 2018 in the open-access journal PLOS ONE by Xueying Han from the Science and Technology Policy Institute, USA, and colleagues.
Prominent academics, including Salk's Thomas Albright, call for more science in forensic science
Six scientists who recently served on the National Commission on Forensic Science are calling on the scientific community at large to advocate for increased research and financial support of forensic science as well as the introduction of empirical testing requirements to ensure the validity of outcomes.
World Science Forum 2017 Jordan issues Science for Peace Declaration
On behalf of the coordinating organizations responsible for delivering the World Science Forum Jordan, the concluding Science for Peace Declaration issued at the Dead Sea represents a global call for action to science and society to build a future that promises greater equality, security and opportunity for all, and in which science plays an increasingly prominent role as an enabler of fair and sustainable development.
PETA science group promotes animal-free science at society of toxicology conference
The PETA International Science Consortium Ltd. is presenting two posters on animal-free methods for testing inhalation toxicity at the 56th annual Society of Toxicology (SOT) meeting March 12 to 16, 2017, in Baltimore, Maryland.
Citizen Science in the Digital Age: Rhetoric, Science and Public Engagement
James Wynn's timely investigation highlights scientific studies grounded in publicly gathered data and probes the rhetoric these studies employ.
Science/Science Careers' survey ranks top biotech, pharma, and biopharma employers
The Science and Science Careers' 2016 annual Top Employers Survey polled employees in the biotechnology, biopharmaceutical, pharmaceutical, and related industries to determine the 20 best employers in these industries as well as their driving characteristics.
Three natural science professors win TJ Park Science Fellowship
Professor Jung-Min Kee (Department of Chemistry, UNIST), Professor Kyudong Choi (Department of Mathematical Sciences, UNIST), and Professor Kwanpyo Kim (Department of Physics, UNIST) are the recipients of the Cheong-Am (TJ Park) Science Fellowship of the year 2016.
More Science News and Science Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Warped Reality
False information on the internet makes it harder and harder to know what's true, and the consequences have been devastating. This hour, TED speakers explore ideas around technology and deception. Guests include law professor Danielle Citron, journalist Andrew Marantz, and computer scientist Joy Buolamwini.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

How to Win Friends and Influence Baboons
Baboon troops. We all know they're hierarchical. There's the big brutish alpha male who rules with a hairy iron fist, and then there's everybody else. Which is what Meg Crofoot thought too, before she used GPS collars to track the movements of a troop of baboons for a whole month. What she and her team learned from this data gave them a whole new understanding of baboon troop dynamics, and, moment to moment, who really has the power.  This episode was reported and produced by Annie McEwen. Support Radiolab by becoming a member today at Radiolab.org/donate.